Download PDF
Der Klinikarzt 2016; 45(12): 616-619
DOI: 10.1055/s-0042-122328
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Chronisch entzündliche Darmerkrankungen

Aktuelle Therapiestrategien und mögliche EntwicklungenInflammatory bowel diseases - Current therapeutic strategies and potential developments
Elena Sonnenberg
1   Medizinische Klinik für Gastroenterologie, Infektiologie, Rheumatologie, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin
,
Britta Siegmund
1   Medizinische Klinik für Gastroenterologie, Infektiologie, Rheumatologie, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin
› Author Affiliations
Further Information

Publication History

Publication Date:
30 December 2016 (online)

Also available at
    Permissions and Reprints

Chronisch entzündliche Darmerkrankungen (CED) mit den beiden Hauptvertretern Morbus Crohn und Colitis ulcerosa zeigen eine zunehmende Inzidenz, ohne dass wir die Pathogenese vollständig verstehen. Präventive Strategien stehen daher aktuell nicht zur Verfügung. Mit dem vorliegenden Artikel werden die aktuellen Therapiestrategien praxisrelevant zusammengefasst. Abschließend sollen im Ausblick die möglichen Entwicklungen der nächsten Jahre diskutiert werden

Inflammatory bowel diseases (IBD) with the two main entities Crohn’s disease as well as ulcerative colitis have been presenting with an increasing incidence over the last decades. Still, the complete understanding of the disease pathogenesis remains to be clarified at this point. Hence, preventive strategies are entirely lacking. With this article we aim to provide a compact summary of the therapeutic strategies according to current guidelines. Last an outlook on the future of IBD therapy will be discussed.

Key words

Inflammatory bowel diseases - Crohn’s disease - ulcerative colitis - biologics - biosimilars
 

  • Literatur

  • 1 Molodecky NA, Soon IS, Rabi DM et al Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54 e42; quiz e30
    CrossrefPubMedGoogle Scholar
  • 2 Ellinghaus D, Jostins L, Spain SL et al Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet 2016; 48: 510-518
    CrossrefPubMedGoogle Scholar
  • 3 Rossen NG, Fuentes S, van der Spek MJ et al Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology 2015; 149: 110-118 e114
    CrossrefPubMedGoogle Scholar
  • 4 Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2: 1041-1048
    CrossrefPubMedGoogle Scholar
  • 5 Dignass A, Preiss JC, Aust DE et al Updated German guideline on diagnosis and treatment of ulcerative colitis. 2011; Z Gastroenterol 2011; 49: 1276-1341
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Laharie D, Bourreille A, Branche J et al Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-1915
    CrossrefPubMedGoogle Scholar
  • 7 Carbonnel F, Colombel JF, Filippi J et al Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. Gastroenterology 2016; 150: 380-388 e384
    CrossrefPubMedGoogle Scholar
  • 8 Feagan BG, Rutgeerts P, Sands BE et al Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710
    CrossrefPubMedGoogle Scholar
  • 9 Preiss JC, Bokemeyer B, Buhr HJ et al Updated German clinical practice guideline on “Diagnosis and treatment of Crohn’s disease” 2014. Z Gastroenterol 2014; 52: 1431-1484
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Sandborn WJ, Feagan BG, Rutgeerts P et al Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369: 711-721
    CrossrefPubMedGoogle Scholar
  • 11 Sandborn W, Gasink C, Blank M et al O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn’s Disease Refractory to Anti-TFNalpha: UNITI-1. Inflamm Bowel Dis 2016; 22 (Suppl. 01) S1
    Google Scholar
  • 12 Park W, Hrycaj P, Jeka S et al A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72: 1605-1612
    CrossrefPubMedGoogle Scholar
  • 13 Yoo DH, Hrycaj P, Miranda P et al A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72: 1613-1620
    CrossrefPubMedGoogle Scholar
  • 14 Baji P, Gulacsi L, Lovasz BD et al Treatment preferences of originator versus biosimilar drugs in Crohn’s disease; discrete choice experiment among gastroenterologists. Scand J Gastroenterol 2016; 51: 22-27
    PubMedGoogle Scholar
  • 15 Farkas K, Rutka M, Golovics PA et al Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis. J Crohns Colitis 2016; 10: 1273-1278
    CrossrefPubMedGoogle Scholar